AGUIAR-LUCANDER RENEE 4

What Happened

• Renee Aguiar‑Lucander, a director of AC Immune SA (ACIU), was granted equity awards on June 11, 2026: 16,568 restricted share units (RSUs) and share options covering 38,889 common shares. Both awards were reported at $0.00 per share (they are grants/awards, not open‑market purchases or sales).

Key Details

• Transaction date: 2026-06-11. Form 4 filed: 2026-06-15 (timely filed within required period).
• RSU grant: 16,568 units, price $0.00 (award) — these convert to common shares upon vesting/settlement per the company plan (SOIP).
• Option grant: options covering 38,889 shares, reported as a derivative award at $0.00; the options will fully vest on June 10, 2027 (per filing).
• Filing note: the filing states "comprised of 51,136 common shares underlying outstanding restricted share units" (per footnote in the filing).
• No cash was paid (awards reported at $0); this is not a sale or open‑market purchase.

Context

• RSUs and option grants are common forms of director compensation; RSUs convert to shares only upon vesting, and options are a derivative right to buy shares if exercised after vesting. Neither grant represents immediate cash proceeds or an immediate change in public float until vesting/exercise and any subsequent sale.
• This filing documents compensation awards to a director and does not by itself indicate a buy or sell decision in the open market.